Background Cardio‐oncology is a clinical discipline focused primarily on the early detection
of anticancer therapy–related cardiomyopathy. However, there is growing evidence that the …

The landscape of cancer therapeutics is continually evolving, with successes in improved
survivorship and reduced disease progression for many patients with cancer. Improved …

Background Previous studies indicated that the (neo) adjuvant chemotherapy for breast
cancer can cause significant dyslipidemia in patients, but how long this abnormality can …

Background/Aim: Chemotherapy-induced cardiotoxicity may be observed during treatment
or may cause severe cardiac failure as the main cause of death, even several years after …

Background: Acute myeloid leukemia (AML) is a common hematological malignancy treated
with regimens containing anthracycline, an agent with cardiotoxicity. However, the cardiac …

Monitoring changes in left ventricular function is the primary surveillance strategy in cardio-
oncology practice for detecting cardiotoxicity in cancer patients actively receiving treatment …

Background The clinical course of penetrating atherosclerotic ulcers is variable and can be
complicated with intramural haematomas, dissection, pseudoaneurysms, or aortic rupture …

Противоопухолевое лекарственное лечение гемобластозов всегда учитывает
коморбидный фон пациента. В связи с частой сердечно-сосудистой патологией и …

Cancer survivors are at an increased risk of morbidities such as cardiovascular diseases
(CVD). Cancer treatments such as chemotherapy and radiation have been correlated with …

Antitumor drug treatment of hemoblastoses always takes into account the patient
comorbidity. Due to the frequent cardiovascular pathology and atherosclerosis, patients …